KI-67 AND CYCLOOXYGENASE-2 EXPRESSIONS IN ODONTOGENIC KERATOCYSTS, DENTAL FOLLICLE AND AMELOBLASTOMA-AN IMMUNOHISTOCHEMICAL STUDY

Abstract

Purpose: Ki-67 and COX-2 are two markers which are commonly used to assess tumor proliferation. The aims of this study were to evaluate and compare the presence of Ki-67 and COX-2 in odontogenic keratocyst (OKC), radicular cyst (RC), ameloblastoma (AML) and dental follicle (DF) in order to determine proliferative potentials of such lesions.
Materials and Methods: This study has been conducted on 80 samples obtained from non-smoking, healthy subjects diagnosed as having either OKC, RC, AML or DF. 20 samples obtained from healthy mucosa served as controls. Slides prepared from paraffin-embedded sections were immunohistochemically stained for Ki-67 and COX-2 expressions.
Results: Ki-67 and COX-2 expressions in the OKC and AML groups were found to be significantly higher than those observed in the RC, DF and healthy mucosa groups (p < 0.005 for each).
Conclusion: High levels of Ki-67 and COX-2 staining in OKC and AML can be considered as the indicators of high proliferation tendency and mitotic activity. These markers could provide valuable tools for the treatment process when they are available for widespread use to detect cases that have significant relapse potential and aggressive behavior.

Keywords

• Odontogenic cysts
• ameloblastoma
• dental follicle
• Ki-67
• COX-2

Odontojen Keratokistler, Dental Foliküller ve Ameloblastomalarda Cyclooxygenase-2 ve Ki67’nin İmmunohistokimyasal Yöntemle Araştırılması

Abstract

Amaç: Ki-67 ve COX-2, tümör proliferasyonunu değerlendirmek için yaygın olarak kullanılan iki belirteçtir. Bu çalışmanın amacı radiküler kist, keratokist, ameloblastoma ve tam gömük yirmi yaş dişlerinin dental folikülündeki Ki-67 ve COX-2 expresyonlarını değerlendirmek ve sağlıklı dokularla karşılaştırmaktır.Gereç ve Yöntem: Bu çalışma sistemik hastalığı bulunmayan, sigara ve ilaç kullanmayan 80 hastadan elde edilen odontojenik keratokist, ameloblastoma, radikuler kist ve dental folikul örnekleri üzerinde yapılmıştır. Sağlıklı mukozalardan alınan 20 adet örnek kontrol grubu olarak değerlendirilmiştir. Hazırlanan kesitlerde Ki-67 ve COX-2 expresyonu immunohistokimyasal yöntemlerle boyanarak araştırılmıştır.Bulgular: Odontojenik keratokist ve ameloblastoma gruplarındaki Ki-67 ve COX-2 ekspresyonları radiküler kist, dental folikül ve sağlıklı mukoza gruplarına göre anlamlı derecede yüksek bulunmuştur (her biri için p < 0.005).Sonuç: Keratokist ve ameloblastomada yüksek bulunan Ki-67 ve COX-2 değerleri bu lezyonların proliferasyon eğilimlerinin ve belirgin mitotik aktivitelerinin göstergesi olarak kabul edilebilirler. Bu belirteçler, yüksek nüks eğilimi olan ve agresif özellik gösterebilecek olguların saptanmasında yaygın olarak kullanıldığında tedavi sürecine belirgin katkıları olacaktır.

Keywords

• Odontojenik kistler
• ameloblastoma
• dental folikül
• Ki-67
• COX-2

References

1. Regezzi JA, Sciubba JJ, Jordan RCK. Oral pathology: clinical pathologic correlations. 5th ed., Philadelphia: Saunders, 200 Neville BW, Damm DD, Allen CM, Bouquot JE. Oral and maxillofacial pathology. 3th ed., Missouri: Saunders Elsevier, 200 Philipsen HP. Keratocystic odontogenic tumour. In: Barnes L, Eveson JW, Reichart P, Sinransky D. (Ed.) Head and neck tumours, WHO classification of tumours. 5th ed., Lyon: IARC Pres, 2005, p.306-7. Bhargava D, Deshpande A, Pogrel MA. Keratocystic odontogenic tumour (KCOT) - a cyst to a tumour. Oral and Maxillofac Surg 2012;16(2):163-70.
2. Ledesma-Montes C, Mosqueda-Taylor A, Carlos-Bregni R, de Leon ER, Palma-Guzman JM, Paez-Valencia C, Meneses-Garcia A. Ameloblastomas: a regional Latin-American multicentric study. Oral Dis 2007;13(3):303-7.
3. Al-Khateeb TH, Bataineh AB. Pathology associated with impacted mandibular third molars in group of Jordanians. J Oral Maxillofac Surg 2006;64(11):159860
4. Adelsperger J, Campbell JH, Coates DB, Summerlin DJ, Tomich CE. Early soft tissue pathosis associated with impacted third molars without pericoronal radiolucency. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;89(4):402-6.
5. Baykul T, Saglam AA, Aydin U, Basak K . Incidence of cystic changes of in radiographically normal impacted lower third molar follicles. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99(5):542-5.
6. Adeyemo WL. Do pathologies associated with impacted lower third molars justify prophylactic removal? A critical review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102(4):448-52.
7. Cabbar F, Güler N, Comunoğlu N, Sençift K, Cöloğlu S . Determination of potential cellular proliferation in the odontogenic epithelia of the dental follicle of the asymptomatic impacted third molars. J Oral Maxillofac Surg 2008;66(10):2004-11.
8. Kanan S, Chandran GJ, Pillai KR, Mathew B, Sujathan K, Nalinakumary KR, Nair MK. Expression of p53 in leukoplakia and squamous cell carcinoma of the oral mucosa: correlation with expression of Kİ67. Clin Mol Pathol 1996;49(3):170-5.

9. Kausch I, Jiang H, Ewerdwalbesloh N, Doehn C, Krüger S, Sczakiel G, Jocham D. Inhibition of Ki-67 in a renal cell carcinoma severe combined immunodeficiency disease mouse model is associated with induction of apoptosis and tumour growth inhibition. BJU Int 2005;95(3):416-20.
10. Bantis A, Giannopoulos A, Gonidi M, Liossi A, Aggelonidou E, Petrakakou E, Athanassiades P, Athanassiadou P. Expression of pl20, Ki-67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value. Cytopathology 2004;15(1):25-31.
11. Cristopher G. Immunhistochemisty of non-Hodgkin lymphoma. In: David D (Ed.) Diagnostic immunhistochemistry. 2nd ed., China: Churchill Livingstone Elseiver, 2006.
12. Hayashi H, Ogawa N, Ishiwa N, Yazawa T, Inayama Y, Ito T, Kitamura H. High cyclin E and low p27/Kipl expressions are potentially poor prognostic factors in lung adenocarcinoma patients. Lung Cancer 2001;34(1):59-65.
13. Jarzabek K, Koda M, Kozlowski L, Mittre H, Sulkowski S, Kottler ML, Wolczynski S. Distinct mRNA, protein expression patterns and distribution of oestrogen receptors a and b in human primary breast cancer: correlation with proliferation marker Ki67 and clinicopathological factors. European J Cancer 2005;41(18):2924-34.
14. Nguyen VN, Mirejovsky P, Mirejovsky T, Melinova L, Mandys V. Expression of cyclin Dl, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2. Acta Histochem 2000;102(3):323-38.
15. Stanton KJ, Sidner RA, Miller GA, Cummings OW, Schmidt CM, Howard TJ, Wiebke EA. Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas. Am J Surg 2003;186(5):486-92.
16. Wiesener B, Hauser-Kronberger CE, Zipperer E, Dietze O, Menzel C, Hacker GW. p34cdc2 in invasive breast cancer: relationship to DNA content, Ki67 index and cerbB-2 expression. Histopathology 1998;33(6):522-30.
17. Morsczeck C, Götz W, Schierholz J, Zeilhofer F, Kühn U, Möhl C, Sippel C, Hoffmann KH . Isolation of precur sor cells (PCs) from human dental follicle of wisdom teeth. Matrix Biol 2005;24(2):155-65.
18. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van de Putte LB, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J 1998;12(12):1063-73.
19. Meric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O, Spano JP. Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 2006;59(1):51-64.
20. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 2004;215(1):1-20.
21. Castealo JE, Bart RD 3rd, DiPerna CA, Sievers EM, Bremner RM . Lung cancer and cyclooxygenase-2. Ann Thorac Surg 2003;76(4):1327-35.
22. Davies GL. Cyclooxygenase-2 and chemoprevention of breast cancer. J Steroid Biochem Mol Biol 2003;86(35):495-9.
23. Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 2003;191(2):125-35.
24. Manchana T, Triratanachat S, Sirisabya N, Vasuratna A, Termrungruanglert W, Tresukosol D. Prevalence and prognostic significance of COX-2 expression in stage IB cervical cancer. Gynecol Oncol 2006;100(3):556-60.
25. Itoh S, Matsui K, Furuta I, Takano Y. Immunhistochemical study on overexpression of cyclooxygenase-2 in squamous cell carcinoma of the oral cavity: its importance as a prognostic predictor. Oral Oncol 2003;39(8):829-35.
26. Kanekura T, Higashi Y, Kanzaki T. Inhibitory effects of 9-cis-retinoic acid and pyrrolidinedithiocarbamate on cyclooxygenase(COX)-2 expression and cell growth in human skin squamous carcinoma cells. Cancer Lett 2000;161(2):177-83.
27. Kawai N, Tsujii M, Tsuji S. Cyclooxygenase and colon cancer. Prostaglandins Other Lipid Mediat 2002;68-69:187-96. Li S, Miner K, Fannin R, Carl Barrett J , Davis BJ. Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium. Gynecol Oncol 2004;92(2):622-7.
28. Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000;6(10):4064-8.
29. Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T, Kanetake H. Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expressions of matrix metalloproteinase-2, and survival. Clin Cancer Res 2003;9(5):1741-9.
30. Nozoe T, Ezaki T, Kabashima A, Baba H, Maehara Y. Significance of immunohistochemical expression of cyclooxygenase-2 in squamous cell carcinoma of the esophagus. Am J Surg 2005;189(1):110
31. Yildirim G, Ataoğlu H, Mihmanli A, Kiziloğlu D, Avunduk MC. Pathologic changes in soft tissues associated with asymptomatic impacted third molars. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;106(1):14-8.
32. Koçak H, Timoçin N, Öz F, Uraz S. Gömük alt akıl dişi çevre dokularının histopatolojik ve immunohistokimyasal değerlendirilmesi. İstanbul Üniv Diş Hek Fak Derg 1994;28(1):83-6.
33. Rakprasitkul S. Pathologic changes in the pericoronal tissues of unerupted third molars. Quintessence Int 2001;32(8):633-8.
34. Curran AE, Damm DD, Drummond JF. Pathologically significant pericoronal lesions in adults: histopathologic evaluation. J Oral Maxillofac Surg 2002;60(6):613-7.
35. Mesgarzadeh AH, Esmailzadeh H, Abdolrahimi M, Shahamfar M . Pathosis associated with radiographically normal follicular tissues in third molar impactions: a clinicopathological study. Indian J Dent Res 2008;19(3):208-12.
36. Edamatsu M, Kumamoto H, Ooya K, Echigo S . Apoptosis-related factors in the epithelial components of dental follicles and dentigerous cysts associated with impacted third molars of the mandible. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99(1):17-23.
37. Gadbail AR, Chaudhary M, Patil S, Gawande M. Actual proliferating index and p53 protein expression as prognostic marker in odontogenic cysts. Oral Dis 2009;15(7):490-8.
38. Kolár Z, Geierová M, Bouchal J, Pazdera J, Zboril V, Tvrdy P. Immunohistochemical analysis of the biological potential of odontogenic keratocysts. J Oral Pathol Med 2006;35(2):75-80.
39. Slootweg PJ. p53 protein and Ki-67 reactivity in epithelial odontogenic lesions. An immunohistochemical study. J Oral Pathol Med 1995;24(9):393-7.
40. Kurokawa H, Zhang M, Matsumoto S, Yamashita Y, Tanaka T, Tomoyose T, Takano H, Funaki K, Fukuyama H, Takahashi T, Sakoda S. The relationship of the histologic grade at the deep invasive front and the expression of Ki-67 antigen and p53 protein in oral squamous cell carcinoma. J Oral Pathol Med 2005;34(10):602-7.
41. Myoung H, Kim MJ, Lee JH, Ok YJ, Paeng JY, Yun PY. Correlation of proliferative markers (Ki-67 and PCNA) with survival and lymph node metastasis in oral squamous cell carcinoma: a clinical and histopathological analysis of 113 patients. Int J Oral Maxillofac Surg 2006;35(11):1005-10.
42. Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO . Cylooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 2002;24(8):792-9.
43. Mohan S, Epstein JB. Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer. Oral Oncol 2003;39(6):537
44. Khodeir MM, Mahmoud SA, Gabal SM, Abou-Sriea MA. Cyclooxygenase-2 Cancer Res 2009;2(1):33-9. van Nes JG, de Kruijf EM, Faratian D, van de Velde CJ, Putter H, Falconer C, Smit VT, Kay C, van de Vijver MJ, Kuppen PJ, Bartlett JM . COX-2 expres sion in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res Treat 2011;125(3):671-85.
45. Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol 2002;33(7):708-14.
46. Tang DW, Lin SC, Chang KW, Chi CW, Chang CS, Liu TY. Elevated expression of cyclooxygenase (COX)-2 in oral squamous cell carcinoma-evidence for COX2 induction by areca quid ingredients in oral keratinocytes. J Oral Pathol Med 2003;32(9):522-9.
47. Sugihara I, Yoshida M, Shigenobu T, Takagi H, Maruyama K, Takeuchi N, Toda M, Inoue M, Nakada H. Different progression of tumor xenografts between mucin-producing and mucin-non-producing mammary adenocarcinoma-bearing mice. Cancer Res 2006;66(12):6175-82.
48. Kelley DJ, Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, Ramonetti JT, Dannenberg AJ. Benzo[a] pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis 1997;18(4):795-9.
49. Weng MW, Hsiao YM, Chen CJ, Wang JP, Chen WC, Ko JL. Benzo(a)pyrene diol epoxide up-regulates COX-2 expression through NF-kappaB in rat astrocytes. Toxicol Lett 2004;151(2):345-55.
50. Tsai CH, Huang FM, Yang LC, Chou MY, Chang YC. Immunohistochemical localization of cyclooxygenase-2 in radicular cyst. Int Endod J 2002;35(10):854-8.
51. Mendes RA, Carvalho JF, van der Waal I. A comparative immunohistochemical analysis of COX-2, p53, and Ki-67 expression in keratocystic odontogenic tumors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;lll(3):333-9. Corresponding Author: Çiğdem ÖZÇAMUR GÜNEŞ
52. Radix Ağız Diş Sağlığı Merkezi 34860 Kartal/İstanbul Phone:[phone] e-mail:[e-mail]